B Werner Apt, G Ingrid Heitmann, L M Isabel Jercic, M Leonor Jofré, V Patricia Muñoz C Del, H Isabel Noemí, V Ana M San Martín, P Jorge Sapunar, H Marisa Torres, A Inés Zulantay
Comité de Parasitología, Departamento de Enfermedades Emergentes y Re-emergentes, Ministerio de Salud, Chile.
Rev Chilena Infectol. 2008 Oct;25(5):384-9, discussion 387. Epub 2008 Oct 1.
As expert consensus has been arisen about universal antiparasitic treatment for all patients infected with Trypanosoma cruzi, most important drugs licensed for Chagas disease treatment are reviewed: nifurtimox and benznidazol, their mechanisms of action, doses, treatment schedules, adverse effects and contraindications. Two other drugs used for Chagas disease treatment, for which a Chilean experience may be exhibited, are allopurinol and itraconazole. Indications for treatment of Chagas disease in immunocompetent patients and immunocompromised hosts are detailed. This chapter refers besides to the evaluation and monitoring of antiparasitic therapy in immunocompromised patients, the availability of drugs and includes various forms facsimiles suggested to perform clinical and laboratory follow up of patients that undergo treatment, indicating the prescribed drug, adverse effects and time of follow up.
由于对于所有感染克氏锥虫的患者进行普遍抗寄生虫治疗已达成专家共识，本文综述了治疗恰加斯病的最重要的已获许可药物：硝呋莫司和苯硝唑，它们的作用机制、剂量、治疗方案、不良反应和禁忌证。另外两种用于治疗恰加斯病且有智利使用经验的药物是别嘌醇和伊曲康唑。详细阐述了免疫功能正常患者和免疫功能低下宿主的恰加斯病治疗指征。本章还涉及免疫功能低下患者抗寄生虫治疗的评估和监测、药物的可及性，并包括为接受治疗的患者进行临床和实验室随访建议采用的各种传真形式，注明所开药物、不良反应和随访时间。
